Interview: Ignasi Biosca, CEO, Reig Jofre, Spain
Prior to joining the family business, Ignasi Biosca spent his career working in online media and internet advertising. Upon becoming CEO of Reig Jofre in 2007, he quickly sought to…
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Iberia, S.L.
Paseo de la Castellana 41 – 3a
28046 Madrid
Spain
Phone: +34 91 310 71 10
Fax: +34 91 310 71 11
www.biogenidec.es
Prior to joining the family business, Ignasi Biosca spent his career working in online media and internet advertising. Upon becoming CEO of Reig Jofre in 2007, he quickly sought to…
Xavi Martí, managing director of Lundbeck Spain, discusses how the affiliate responds to the challenge of social stigma surrounding mental diseases and new strategies to open up the company’s portfolio…
Key to improve the Chilean health care system is providing continuous training programs and sharing knowledge with healthcare professionals”, explains Cécile Bassereau, Managing Director B Braun Chile. B. Braun has…
As a leading company in the hospital sector, Roche Spain undoubtedly felt the effects of austerity measures imposed by Spanish health authorities since 2010. Nevertheless, the affiliate has remained in…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Owned completely by the LEO Foundation, LEO Pharma is an extremely patient-centric company focused primarily in the dermatology area. Kristian Hart-Hansen, general manager of LEO Pharma Spain, discusses the challenges…
In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains…
In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains…
Raúl Díaz-Varela is the CEO of Kern Pharma and has served as president of Spain’s generics association AESEG since 2008. He speaks to us about the challenges facing generic companies,…
Jesús Sobrino was appointed general manager of UCB Iberia in 2010, at the same time the pharma market began to seriously contract in Spain. Sobrino discusses adapting to these changes…
PharmaBoardroom first interviewed Erik Lommerde as general manager of Novo Nordisk Netherlands four years ago. In his new role as general manager of Novo Nordisk Spain & Portugal, he discusses…
Invest in Catalonia discuss the Spanish region’s track record when it comes to the pharmaceutical and biotech sectors, where investment is going today in the region, and the factors that…
See our Cookie Privacy Policy Here